GSK's Jemperli/Chemo Combo Shows Response Rate Of 46% In Head-To-Head Lung Cancer Trial

GSK plc GSK announced results from the PERLA phase 2 trial investigating Jemperli (dostarlimab) + chemotherapy versus Merck & Co Inc's MRK Keytruda pembrolizumab + chemo as a first-line treatment for metastatic non-squamous non-small cell lung cancer (NSCLC).
Dostarlimab plus chemotherapy achieved promising results for the primary endpoint of confirmed objective response rate (ORR) and the key secondary endpoint of median progression-free survival (mPFS).
The ORR was 46% (n=56/121) in the dostarlimab treatment arm versus 37% (n=45/122) in the pembrolizumab treatment arm.
Also see: After Disappointing Confirmatory Study, GSK To Withdraw Approved Blood Cancer Drug In US.
The key secondary endpoint, mPFS, was 8.8 months in the dostarlimab treatment arm versus 6.7 months in the pembrolizumab treatment arm.
Treatment-emergent adverse events (TEAEs) for dostarlimab in the PERLA phase II trial were consistent with previous trials of similar regimens. The most common TEAEs were anemia, asthenia, nausea, constipation, cough, dyspnoea, vomiting, decreased appetite, and neutropenia.
GSK is also studying dostarlimab in earlier lines of treatment for endometrial cancer and combination with other therapeutic agents for patients with advanced/metastatic cancers.
Price Action: GSK shares are down 2.78% at $36.87 on the last check Wednesday.